Bayer to Explore Sale of $1.1 Billion Dermatology Business
Bayer AG is exploring the sale of its dermatology business, according to people familiar with the matter, as the German drugmaker sells peripheral businesses and pursues the takeover of crop chemicals rival Monsanto Co.
The German company is working with JPMorgan Chase & Co. on the sale, which could fetch more than 1 billion euros ($1.1 billion), said the people, asking not to be identified because talks are private. The process is at an early stage and Bayer could decide against a disposal, they said.
The German company is working with JPMorgan Chase & Co. on the sale, which could fetch more than 1 billion euros ($1.1 billion), said the people, asking not to be identified because talks are private. The process is at an early stage and Bayer could decide against a disposal, they said.